| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/CIRCRESAHA.111.250266 |
| P8608 | Fatcat ID | release_idx4nql6avfovigojxb2jqnsmm |
| P932 | PMC publication ID | 3706265 |
| P698 | PubMed publication ID | 23371902 |
| P2093 | author name string | Mark Mercola | |
| Erik Willems | |||
| Alexandre Colas | |||
| P2860 | cites work | A genome-scale RNAi screen for Oct4 modulators defines a role of the Paf1 complex for embryonic stem cell identity | Q24312181 |
| MicroRNAs: target recognition and regulatory functions | Q24609584 | ||
| Disease-specific induced pluripotent stem cells | Q24641981 | ||
| The impact of microRNAs on protein output | Q24653549 | ||
| Most mammalian mRNAs are conserved targets of microRNAs | Q24655061 | ||
| Induced pluripotent stem cell lines derived from human somatic cells | Q27860597 | ||
| Widespread changes in protein synthesis induced by microRNAs | Q27860886 | ||
| Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? | Q27860893 | ||
| Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors | Q27860937 | ||
| microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart | Q40036277 | ||
| Identification of human microRNA targets from isolated argonaute protein complexes | Q40105925 | ||
| An information-intensive approach to the molecular pharmacology of cancer. | Q41134023 | ||
| RISC RNA sequencing for context-specific identification of in vivo microRNA targets | Q41835167 | ||
| Isolation of microRNA targets by miRNP immunopurification | Q42530176 | ||
| A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects | Q42815540 | ||
| Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification | Q42817633 | ||
| Role of Ca(2+)/calmodulin-dependent protein kinase II in the regulation of the cardiac L-type Ca(2+) current during endothelin-1 stimulation | Q43122876 | ||
| Progressive maturation in contracting cardiomyocytes derived from human embryonic stem cells: Qualitative effects on electrophysiological responses to drugs | Q43143897 | ||
| A genome-wide RNAi screen identifies a new transcriptional module required for self-renewal | Q43148740 | ||
| Na+-dependent SR Ca2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation. | Q43191839 | ||
| Altered cytosolic Ca2+ dynamics in cultured Guinea pig cardiomyocytes as an in vitro model to identify potential cardiotoxicants | Q43197546 | ||
| Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. | Q50506853 | ||
| Mitochondria determine the differentiation potential of cardiac mesoangioblasts. | Q53250129 | ||
| Metabolite utilization by isolated embryonic rat hearts in vitro | Q69396500 | ||
| Myocardial oxygen and carbohydrate consumption in fetal lambs in utero and in adult sheep | Q71175696 | ||
| Mutant ryanodine receptors in catecholaminergic polymorphic ventricular tachycardia generate delayed afterdepolarizations due to increased propensity to Ca2+ waves | Q79906106 | ||
| Cardiotoxicity of antitumor drugs | Q80982459 | ||
| Induction of pluripotent stem cells from adult human fibroblasts by defined factors | Q27860967 | ||
| Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen | Q28146108 | ||
| Reprogramming of human somatic cells to pluripotency with defined factors | Q28262710 | ||
| How many drug targets are there? | Q28276660 | ||
| Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2 | Q28295844 | ||
| Navigating chemical space for biology and medicine | Q28298611 | ||
| How to improve R&D productivity: the pharmaceutical industry's grand challenge | Q28314992 | ||
| Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations | Q28483390 | ||
| A cardiac microRNA governs systemic energy homeostasis by regulation of MED13 | Q28505950 | ||
| Whole-genome microRNA screening identifies let-7 and mir-18 as regulators of germ layer formation during early embryogenesis | Q28506223 | ||
| MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts | Q28511032 | ||
| Control of stress-dependent cardiac growth and gene expression by a microRNA | Q28587851 | ||
| Molecular regulation of vascular smooth muscle cell differentiation in development and disease | Q29615194 | ||
| Can the pharmaceutical industry reduce attrition rates? | Q29616077 | ||
| How were new medicines discovered? | Q29616641 | ||
| Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines | Q29616799 | ||
| Modelling the long QT syndrome with induced pluripotent stem cells | Q29620092 | ||
| Patient-specific induced pluripotent stem-cell models for long-QT syndrome | Q29620353 | ||
| The chemical hunt for the identification of drugable targets. | Q30342800 | ||
| Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. | Q30489278 | ||
| Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome | Q30499663 | ||
| Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. | Q30539904 | ||
| Measurement of intracellular calcium | Q30784217 | ||
| Chemical genetics: ligand-based discovery of gene function | Q31881396 | ||
| Cardiogenic small molecules that enhance myocardial repair by stem cells | Q33329047 | ||
| A comparative analysis of standard microtiter plate reading versus imaging in cellular assays | Q33369922 | ||
| Target profiling of small molecules by chemical proteomics | Q33494810 | ||
| Ago2 immunoprecipitation identifies predicted microRNAs in human embryonic stem cells and neural precursors. | Q33507081 | ||
| Automated microscopy for high-content RNAi screening | Q33533546 | ||
| High-throughput screening in embryonic stem cell-derived neurons identifies potentiators of alpha-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate-type glutamate receptors | Q33538463 | ||
| Increased Ca2+ sensitivity of the ryanodine receptor mutant RyR2R4496C underlies catecholaminergic polymorphic ventricular tachycardia | Q33551271 | ||
| Targeting the undruggable proteome: the small molecules of my dreams | Q33627085 | ||
| microRNAs in heart disease: putative novel therapeutic targets? | Q33728265 | ||
| Regulation of PI3-kinase/Akt signaling by muscle-enriched microRNA-486 | Q33732748 | ||
| An ovine transgenic Huntington's disease model | Q33815561 | ||
| Towards the maturation and characterization of smooth muscle cells derived from human embryonic stem cells | Q33851711 | ||
| In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells | Q37005193 | ||
| A chemical genetics approach for specific differentiation of stem cells to somatic cells: a new promising therapeutical approach | Q37065381 | ||
| Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth | Q37182706 | ||
| Regional heterogeneity within the aorta: relevance to aneurysm disease | Q37184608 | ||
| Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β-adrenergic stimulation | Q37294805 | ||
| The emerging role of microRNAs in cardiac remodeling and heart failure | Q37319218 | ||
| Simple vertebrate models for chemical genetics and drug discovery screens: lessons from zebrafish and Xenopus. | Q37481066 | ||
| Technical challenges in using human induced pluripotent stem cells to model disease | Q37642100 | ||
| Electrophysiological challenges of cell-based myocardial repair | Q37653423 | ||
| Functional properties of human embryonic stem cell-derived cardiomyocytes | Q37763235 | ||
| Staying on message: design principles for controlling nonspecific responses to siRNA. | Q37809577 | ||
| RNA-based therapeutics: current progress and future prospects. | Q37979387 | ||
| Progress in the reprogramming of somatic cells | Q38078312 | ||
| Direct cardiac reprogramming: from developmental biology to cardiac regeneration | Q38136922 | ||
| Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease | Q39339606 | ||
| Derivation of endothelial cells from human embryonic stem cells by directed differentiation: analysis of microRNA and angiogenesis in vitro and in vivo | Q39709094 | ||
| Quantified proarrhythmic potential of selected human embryonic stem cell-derived cardiomyocytes. | Q39725570 | ||
| Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes | Q39759039 | ||
| Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome | Q33910479 | ||
| Small-molecule inhibitors of the Wnt pathway potently promote cardiomyocytes from human embryonic stem cell-derived mesoderm | Q33954234 | ||
| A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes | Q33975776 | ||
| Harnessing the potential of induced pluripotent stem cells for regenerative medicine | Q34182222 | ||
| Small molecule-mediated TGF-β type II receptor degradation promotes cardiomyogenesis in embryonic stem cells | Q34292182 | ||
| Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry. | Q34307706 | ||
| Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells | Q34322985 | ||
| Steps toward safe cell therapy using induced pluripotent stem cells | Q34325607 | ||
| Drug-induced long QT syndrome | Q34358104 | ||
| Functional screening identifies miRNAs inducing cardiac regeneration. | Q34504097 | ||
| Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 | Q34764750 | ||
| Genetic basis of thoracic aortic aneurysms and dissections: focus on smooth muscle cell contractile dysfunction | Q34785796 | ||
| Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation | Q34793218 | ||
| Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome | Q34930935 | ||
| Lost in translation: an assessment and perspective for computational microRNA target identification | Q35005629 | ||
| Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development | Q35095735 | ||
| Mitochondrial oxidative metabolism is required for the cardiac differentiation of stem cells | Q35596393 | ||
| Skeletogenic phenotype of human Marfan embryonic stem cells faithfully phenocopied by patient-specific induced-pluripotent stem cells | Q35657562 | ||
| Generation of human vascular smooth muscle subtypes provides insight into embryological origin-dependent disease susceptibility | Q35737818 | ||
| Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs | Q35789021 | ||
| Arrhythmogenic mechanisms of QT prolonging drugs: is QT prolongation really the problem? | Q35944111 | ||
| Exploring biology with small organic molecules | Q35986043 | ||
| Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia | Q36037969 | ||
| Techniques: high-throughput measurement of intracellular Ca(2+) -- back to basics. | Q36088557 | ||
| Simultaneous voltage and calcium mapping of genetically purified human induced pluripotent stem cell-derived cardiac myocyte monolayers | Q36176876 | ||
| Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends | Q36313699 | ||
| Engineering myocardial tissue | Q36336909 | ||
| Systematic identification of C. elegans miRISC proteins, miRNAs, and mRNA targets by their interactions with GW182 proteins AIN-1 and AIN-2. | Q36344405 | ||
| A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia | Q36496218 | ||
| Misconceptions about calcimimetics | Q36532586 | ||
| Preclinical cardiovascular risk assessment in modern drug development | Q36757160 | ||
| Immunogenicity of pluripotent stem cells and their derivatives | Q36802900 | ||
| High throughput measurement of Ca²⁺ dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry | Q36886861 | ||
| P433 | issue | 3 | |
| P921 | main subject | circulatory system | Q11068 |
| drug discovery | Q1418791 | ||
| P304 | page(s) | 534-548 | |
| P577 | publication date | 2013-02-01 | |
| P1433 | published in | Circulation Research | Q2599020 |
| P1476 | title | Induced pluripotent stem cells in cardiovascular drug discovery | |
| P478 | volume | 112 |
| Q27330969 | A Systemized Approach to Investigate Ca(2+) Synchronization in Clusters of Human Induced Pluripotent Stem-Cell Derived Cardiomyocytes |
| Q28818732 | A chemical-biological similarity-based grouping of complex substances as a prototype approach for evaluating chemical alternatives |
| Q42700209 | An Automated Platform for Assessment of Congenital and Drug-Induced Arrhythmia with hiPSC-Derived Cardiomyocytes |
| Q35181554 | An early requirement for nkx2.5 ensures the first and second heart field ventricular identity and cardiac function into adulthood |
| Q35008383 | Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity |
| Q39126913 | Bringing new dimensions to drug discovery screening: impact of cellular stimulation technologies |
| Q30557177 | CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia. |
| Q91790482 | Cardiac Toxicity From Ethanol Exposure in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes |
| Q38837706 | Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative. |
| Q26798131 | Cardiovascular Disease Modeling Using Patient-Specific Induced Pluripotent Stem Cells |
| Q41783099 | Cardiovascular Organ-on-a-Chip Platforms for Drug Discovery and Development |
| Q38601752 | Concise Review: Fluorescent Reporters in Human Pluripotent Stem Cells: Contributions to Cardiac Differentiation and Their Applications in Cardiac Disease and Toxicity |
| Q34976035 | Developing microRNA screening as a functional genomics tool for disease research |
| Q48061816 | Differentiation of cardiomyocytes and generation of human engineered heart tissue |
| Q35620068 | Efficient and scalable expansion of human pluripotent stem cells under clinically compliant settings: a view in 2013 |
| Q36419596 | Efficient differentiation of human embryonic stem cells to arterial and venous endothelial cells under feeder- and serum-free conditions. |
| Q47418556 | ErbB Receptor Tyrosine Kinase: A Molecular Switch Between Cardiac and Neuroectoderm Specification in Human Pluripotent Stem Cells |
| Q28542837 | Evaluation of the cardiotoxicity of mitragynine and its analogues using human induced pluripotent stem cell-derived cardiomyocytes |
| Q38559308 | Evolving targeted therapies for right ventricular failure |
| Q36365384 | Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes |
| Q26772221 | G-protein Coupled Receptor Signaling in Pluripotent Stem Cell-derived Cardiovascular Cells: Implications for Disease Modeling |
| Q30390374 | High content screening for modulators of cardiac differentiation in human pluripotent stem cells |
| Q36948480 | High throughput physiological screening of iPSC-derived cardiomyocytes for drug development. |
| Q37378179 | Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity |
| Q38201684 | Human pluripotent stem cell-derived retinal pigmented epithelium in retinal treatment: from bench to bedside |
| Q41590446 | Id genes are essential for early heart formation |
| Q27320909 | Identification and purification of human induced pluripotent stem cell-derived atrial-like cardiomyocytes based on sarcolipin expression |
| Q32181083 | In vitro cardiotoxicity assessment of environmental chemicals using an organotypic human induced pluripotent stem cell-derived model |
| Q38242113 | Induced Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Neurodegenerative Diseases |
| Q38203865 | Induced pluripotent stem cells for post-myocardial infarction repair: remarkable opportunities and challenges. |
| Q38786687 | Induced pluripotent stem cells: at the heart of cardiovascular precision medicine |
| Q35154388 | Integrating omics into the cardiac differentiation of human pluripotent stem cells |
| Q34153953 | Measuring the contractile forces of human induced pluripotent stem cell-derived cardiomyocytes with arrays of microposts |
| Q36600856 | Micropost arrays for measuring stem cell-derived cardiomyocyte contractility |
| Q28255887 | Modelling sarcomeric cardiomyopathies in the dish: from human heart samples to iPSC cardiomyocytes |
| Q34494232 | Monitoring Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes with Genetically Encoded Calcium and Voltage Fluorescent Reporters |
| Q59072379 | Myocardial Reprogramming Medicine: The Development, Application, and Challenge of Induced Pluripotent Stem Cells |
| Q27334228 | N-glycans: phenotypic homology and structural differences between myocardial cells and induced pluripotent stem cell-derived cardiomyocytes |
| Q49775265 | Nonlinear mixed effects dose response modeling in high throughput drug screens: application to melanoma cell line analysis. |
| Q100418595 | Patient-specific genomics and cross-species functional analysis implicate LRP2 in hypoplastic left heart syndrome |
| Q38235190 | Pluripotent stem cells as a platform for cardiac arrhythmia drug screening |
| Q35724421 | Prospects for In Vitro Myofilament Maturation in Stem Cell-Derived Cardiac Myocytes |
| Q39023966 | Rapid cellular phenotyping of human pluripotent stem cell-derived cardiomyocytes using a genetically encoded fluorescent voltage sensor |
| Q41573786 | Real-Time Force and Frequency Analysis of Engineered Human Heart Tissue Derived from Induced Pluripotent Stem Cells Using Magnetic Sensing. |
| Q41869132 | Recapitulation of Clinical Individual Susceptibility to Drug-Induced QT Prolongation in Healthy Subjects Using iPSC-Derived Cardiomyocytes |
| Q39050847 | Recreating the Cardiac Microenvironment in Pluripotent Stem Cell Models of Human Physiology and Disease |
| Q33716314 | Reprogramming the cardiac field |
| Q36734551 | Reverse engineering human neurodegenerative disease using pluripotent stem cell technology |
| Q26799470 | Tissue engineering the cardiac microenvironment: Multicellular microphysiological systems for drug screening |
| Q43868547 | Turning Potential Into Action: Using Pluripotent Stem Cells to Understand Heart Development and Function in Health and Disease. |
| Q55486639 | Uninterrupted monitoring of drug effects in human-induced pluripotent stem cell-derived cardiomyocytes with bioluminescence Ca2+ microscopy. |
| Q58568612 | Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity |
Search more.